Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Disagree, a 20% move in a week; touching the Fib. Line and MA should send this back to the 50’s for a few days to weeks before the next move.
Thoughts on a bounce tomorrow? Feels like 18% seems like overkill.
Overbought because many believe this finally turned a corner and have weighed it to be undervalued at this point.
Well what would cause people to sell right now?
Chart shows around 125-150 million shares have churned in the 18-18.50 range since may 1st. About 15-21 % of total outstanding shares. Few more days in that range will create a nice step IMO.
Historically yes it's in a down trend and has been for months. Even though I agree and expect a pullback from the run up I believe the trend has turned and we should begin seeing the bulls take control of the stock in the coming months.
I think this has a good chance of breaking that resistance. Fundamentals have changed and momentum is currently pushing up, a close above the 200MA will be the strongest indicator today I believe.
Means without good news there will be a slow sell off as investors lose patience/trust in management.
This information is in the public domain, it should already be baked into the Price. A transparent fed shouldn't make big waves in the market.
So we've seen analysts suggest Twitter is worth anywhere from $17 a share to $42. At this point I'm pretty sure anyone can throw a dart at a board when your +\- is 15 billion.
Twtr new HOD $24.94, hoping to see a break through $25. Test some new levels.
News:
By Monica Langley Twitter Inc. is expected to field bids this week, according to people familiar with the matter, in a sign the long-awaited sale of the social-media pioneer could soon be at hand. Among the bidders is Salesforce.com Inc., whose recent approach to Twitter helped kick off the bidding process. Salesforce Chief Executive Marc Benioff is looking to make a splashy acquisition that would secure a treasure trove of data as well as a prized consumer brand. Mr. Benioff sees the popular messaging service as an "unpolished jewel" with untapped potential in advertising, e-commerce and other data-rich applications he regards as important to the cloud-software juggernaut's next phase of growth, according to people familiar with the matter. But the brash CEO, who lost out to Microsoft Corp. in a bitter battle to buy LinkedIn Corp. this spring , faces formidable obstacles. Alphabet Inc.'s Google may bid also, the people said, while media giant Walt Disney Co. has been considering its own offer. While Twitter could cost upward of $20 billion, or more than a third of Salesforce's roughly $49 billion market value, it would be more bite-sized for Google, the search powerhouse whose parent sports a market value of more than $500 billion. Disney, meanwhile, has a market capitalization of nearly $150 billion. There is no guarantee any bid will come in high enough to entice Twitter to sell, and the company could remain independent. Salesforce investors so far have been cool to the prospect of a deal with Twitter, which is beset with challenges. Owning it would also vault Salesforce outside its comfort zone as a provider of cloud-based services for businesses, which helped pioneer the concept of selling software as a service over the internet. But Mr. Benioff clearly has a gleam in his eye for Twitter, which generates untold reams of data from its hundreds of millions of users and offers potential as a tantalizing turnaround opportunity. "Data is the currency in software's new world order," he said in an interview this past weekend, though he wasn't specifically speaking about Twitter. "I'm looking hard at unique data-rich companies and what I can do to make them more powerful and innovative if combined with Salesforce." At a private dinner recently, Mr. Benioff told a dozen tech CEOs that Twitter is an "unpolished jewel," according to a person who attended. "Twitter is a great brand," he told the CEOs, and he wants to "make it a great company," according to the person. Like LinkedIn, Twitter could bring Salesforce reams of data to create recommendations and insights for its corporate customers. Twitter could complement Mr. Benioff's goal of harnessing more data for artificial-intelligence-driven analysis, as well as allow Salesforce to offer additional services in sales, marketing and e-commerce for the company's 150,000 customers. Both Salesforce and its CEO already have ties to Twitter. Mr. Benioff and Twitter Chief Executive Jack Dorsey live in the same tony San Francisco neighborhood. Salesforce already incorporates Twitter in numerous cloud services for its corporate customers, from service complaints handled through tweets to analysis of tweets on products. The exuberant Mr. Benioff, who became a billionaire as Salesforce's stock rose ninefold in the past decade, sees numerous benefits from bringing the companies more closely together. According to a person familiar with his thinking, Mr. Benioff is convinced a strong partner could figure out how to better monetize Twitter's big user base and fire hose of content, something the social-media company has struggled with. At first blush, Twitter, a strong consumer brand, seems an unlikely fit for the corporate-focused Salesforce. In acquiring Twitter, Salesforce would take on a host of problems that have dogged the social-media company, including its struggles to reinvigorate user growth and combat some of its users' abusive behavior. Twitter would also be a much bigger acquisition than Mr. Benioff has ever done before. Mr. Benioff's M&A focus is "the single biggest overhang" on Salesforce stock, UBS Group AG software analyst Brent Thill said. After Salesforce failed to meet its billings forecast and revenue guidance in its most recent quarter, some investors worry about the health of its core business and want the company to focus on that. Yet, "if Marc goes this big, the market might ultimately give him a pass because he changed the industry," Mr. Thill said. "Marc has shown vision and backed it up with financial proof. Now he may tell investors that in return for short-term pain, prepare for long-term gain." Indeed, Mr. Benioff said in the interview that he would assure investors at the company's Dreamforce customer conference in San Francisco Wednesday that, regardless of whether it makes a big purchase, Salesforce will continue to deliver "excellent operating results." He added: "In reality, we've not altered our mindful approach to acquisitions." Salesforce has made a number of purchases lately. In July, it bought e-commerce specialist Demandware Inc. for $2.8 billion, Salesforce's largest takeover to date. This week, it agreed to buy San Francisco startup Krux for about $700 million in a bid to bolster the artificial-intelligence capacity in Salesforce's marketing cloud. Mr. Benioff said he is spending about 25% of his time on M&A this year. In addition to the bid for Twitter and the Krux deal, Salesforce is appealing to U.S. and European regulators to scuttle or revise Microsoft's $26 billion planned acquisition of LinkedIn, another deep well of valuable data. He has complained about the LinkedIn sales process. Mr. Benioff said his goal was to get Microsoft to open up LinkedIn's huge repository of individual and company profiles, rather than allow the software giant to wield it as competitive advantage against Salesforce and other enterprise-software companies. Write to Monica Langley at monica.langley@wsj.com (END) Dow Jones Newswires October 04, 2016 18:46 ET (22:46 GMT) Copyright (c) 2016 Dow Jones & Company, Inc.
November 2014, seriously?? Why are you here.
Pps is determined by the market, pls give an explanation as to why "da moon" is relevant here? Seeing as the market does not agree with you and it's well below your moon shot expectations. My point is stop pumping your dead horse. You've lost. It's not going to recover to $700. Cut your losses now and get back in at a new low. It will rise eventually; just not to "da moon" as it sits currently
$196.50
Yes, when the underlying circumstances don't affect the fundamentals of the company, VRX just had its core ripped out and turned upside down, price gouging won't be stood for by the gvmt.(Hillary called them out on this). Where do you see future profits coming from? I see a company upside down drowning in debt, any profits will go towards paying down those debts for years to come.
Appears CMG looking to retest the year lows, could see a nice drop later today.
Sold 2 of mine, holding last 2 looking for $390 exit
Nope, direct correlation. Based on past performance a quiet period probably doesn't mean good news. Bto 4 p $415 at 3.70 avg yesterday. Looks like the right choice so far.
Take a look at the 3-4 month chart, massive run up from $142 the year low. IMO I believe what the analysts say that this is extremely overvalued in comparison to other established car companies. I believe it's trading more like a tech company with these massive swings and valuations projecting massive growth (think FANG stocks). I personally won't be "investing" in this stock any time soon but look to play the waves on both sides. I love the tesla brand but isn't where I would stash my money long term currently. I do hope the company succeeds though, believe Musk has the right visions for the company.
My take: This is obviously a big step back for management and PVCT. It appeared they were confident with BTD approval and made all the right steps towards that from a shareholders standpoint. As new information comes to light it is clear they ignored advice from the FDA in terms of endpoint statistically significant information. Now nowhere does the press release state the FDA does not think this is a viable drug, it simply states this drug has yet to without a doubt statistically prove its is better than anything else on the market. This does NOT mean the drug does not work or will not make it to market. What I am looking for is a CLEAR path to approval from this application. Don't dick around and submit another BTD application before having all required information the FDA is looking for. This is obviously going to set the price back significantly come Monday morning, that is to be expected congrats to those who correctly shorted. However for those who believe in this drug (which it clearly works) this is going to add at least 1-2 years to the endgame. Close your eyes these next few days while this yo-yos between nothing and $1. Going ahead it looks as though management will need a new plan moving forward. Best scenario they are bought out but will be less than desired as BTD is a large chink in the armor. Next best they will partner with a large pharma who can fund these PIII trials. It is in PVCT best interest to get this figured out before Monday morning as the questions from investors will undoubtedly slow them. My message to Craig Dees: you MUST ( can't enforce this enough) have a clear path to approval and clearly communicated this to investors. Big pharma can read results, they will become serious in bidding when PVCT actually poses a threat to their bottom line. As it stands they do not. As the FDA agreed, move forward with your Phase three and figure out funding NOW for the sake of your investors.
From: everyone who believed in you
He didn't hear anything. That information would not get out of the room until they say so.
It was a conscious decision by management to help with questions from investors and the media.
Not an FDA mandate. Follow up with PVCT before speculating.
Thanks, Feel like some new info should be up there
PLEASE STICKY THIS INFORMATION
https://www.sec.gov/cgi-bin/browse-edgar?company=Provectus&owner=exclude&action=getcompany
See above information regarding recent filings with PVCT. Read through and educate yourselves before asking questions you can answer.
That's what I was looking for, figured there was a clause somewhere, didn't have time to read all the print yet. That's good news to me. Guaranteed to be new information supporting the story of PVCT.
ASCO - Abstracts Information
http://www.asco.org/press-center/2014-asco-annual-meeting-press-program-highlight-major-advances-cancer-research
Looks like were waiting till 5-14-14 for the press release, makes sense PVCT does not want information getting out before the FDA can come to a decision.
Embargoed Press Release: In journalism and public relations, a news embargo or press embargo is a request by a source that the information or news provided by that source not be published until a certain date or certain conditions have been met. The understanding is that if the embargo is broken by reporting before then, the source will retaliate by restricting access to further information by that journalist or his publication, giving them a long-term disadvantage relative to more cooperative outlets. They are often used by businesses making a product announcement, by medical journals, and by government officials announcing policy initiatives; the media is given advance knowledge of details being held secret so that reports can be prepared to coincide with the announcement date and yet still meet press time. In theory, press embargoes reduce inaccuracy in the reporting of breaking stories by reducing the incentive for journalists to cut corners in hopes of "scooping" the competition. *Wiki-Fairly reliable definition source
Yes, but it's also only allowed to accredited investors. Any information they tell those investors that haven't been made public will have to be made public. This is the only reason they are allowed to keep it somewhat under wraps until they want it to be public information.
"Rumor has indicated that it might have been possible to close a Chinese license deal in the short term, but that doing it before the FDA awarded Breakthrough Therapy Designation (BTD) to PV-10 would be less lucrative. The most important implication of this is not that Provectus may get more money. In fact, for shareholders, the amount of money a Chinese company pays up-front is likely of little or no importance. More on that, later.
The important take-away from this development is that Provectus Management seems supremely confident that they will be awarded BTD status for PV-10. Surely, the price to be paid for licensing would be greater after a BTD award and lower if the BTD application is rejected... even lower than if a deal had been made before the ruling."
Agrossfarms best comment in that post today
http://www.trustintelligence.com/forum/viewtopic.php?id=1929&p=7
Anyone Have an L2 handy for PVCT?
We're only 3 weeks in of a possible 8 before we hear from the FDA on BTD Approval. So there's a potential 5 weeks of churning time before we hear the results. Day traders obviously don't want to let cash sit in a position for 5 weeks when it could be making money somewhere else. Others may believe support at this level is weak and could pick up shares closer to that $2 magnet. I think in the longer term this has potential to be a big winner pending uplisting & BTD approval. With those two items in place I think everything else will fall into order pretty quickly.
Big things happening, pvct seems to be on the right track. Would like to see an uplisting to the AMEX. Be taken much more seriously than the OTC.
Article on Dermatology Times mentions PV-10
http://dermatologytimes.modernmedicine.com/dermatology-times/news/investigational-drug-pv-10-decreases-melanoma-cells-tumors?contextCategoryId=116
DD By Agrossfarm
Is the creator of the original PVCT valuation able to take a stab at the new numbers? I'm sure it would be appreciated by many. Fingers crossed it was an excel file with proper equations to save many hours of work.
PVCT Accumulation currently showing 83k shares this morning. Showing 323K over a 5 day chart. Shows very strong buying happening. Any guesses as to what point sellers will step in and test the new support levels?
Business Wire
Apr 01, 2014 06:30:00 (ET)
PV-10 Selected for Poster Highlights Session
McCormick Place in Chicago, IL, May 30-June 3, 2014
KNOXVILLE, Tenn.--(BUSINESS WIRE)--April 01, 2014--
Provectus Biopharmaceuticals, Inc. (OTCQB:PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced today that data on treatment of cutaneous melanoma using its investigational drug PV-10 have been selected to be part of the Poster Highlights Session of the American Society of Clinical Oncology (ASCO) Annual Meeting this year at McCormick Place, Chicago, IL, May 30-June 3, 2014. The time and date of the session are expected to be available on the ASCO website, http://am.asco.org, on April 21, 2014.
Sanjiv S. Agarwala, MD, is lead author of abstract #9027, entitled "Efficacy of intralesional Rose Bengal in patients receiving injection of all existing melanoma in phase II study PV-10-MM-02."
Craig Dees, PhD, CEO of Provectus said, "Being selected for the Poster Highlights Session is an honor, and we look forward to sharing the results of our Phase 2 study with attendees."
Provectus has recently submitted an application to the FDA for breakthrough therapy designation for PV-10 based on the results from its Phase 2 clinical study related to cutaneous melanoma and is researching its efficacy for other indications.
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals specializes in developing oncology and dermatology therapies. Its novel oncology drug PV-10 is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. Its dermatological drug PH-10 also targets abnormal or diseased cells, with the current focus on psoriasis and atopic dermatitis. Provectus has recently completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis. Information about these and the Company's other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus please visit the Company's website at www.pvct.com or contact Porter, LeVay & Rose, Inc.
FORWARD-LOOKING STATEMENTS: The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date thereof.
CONTACT: Provectus Biopharmaceuticals, Inc.
Peter R. Culpepper, CFO, COO
866-594-5999 #30
I like the confidence behind management in believing in the BTD approval with a fall back of accelerated approval. Both are difficult to obtain and shows some good faith behind their work. Pvct article loaded with good info. A Must read if you can handle all the science behind it.
Interesting website by the FDA with some stats and explanation of what exactly PVCT is trying to accomplish.
http://www.fda.gov/regulatoryinformation/legislation/federalfooddrugandcosmeticactfdcact/significantamendmentstothefdcact/fdasia/ucm341027.htm
Reminder to many of you:
The O/S Was raised to 9.8 BILLION with 3.8 BILLION outstanding as of Jan 24th. As much as you would like to see this fly, there is still 6 billion shares ready for sale. No buying power from anyone is able to help those numbers. Until this O/S is fixed anyone claiming to be long is either trading with daddy's money or never finished elementary school math. BBDA does not have the infrastructure nor output to necessitate 3.8 billion shares currently. Any Bank would throw out a line of credit if BBDA needed the money for expansion; pending they are actually pulling profit based off these incomplete financial reports. It looks clear BBDA is tapping the markets (as many companies do) but they are abusing the shareholders in the process. Explain how you expect 3.8 billion shares (with the possibility of 6 billion more) to go up in price without an R/S or buyback into the millions worth more than the actual company? These are all red flags. I'm not looking to burst anyone's bubble but just keep those very important numbers in the back of your mind when trading.
https://wyobiz.wy.gov/Business/FilingDetails.aspx?eFNum=139156196253141251029028070039008175089079194136
http://www.otcmarkets.com/stock/BBDA/company-info